SYNTHESIS, ANTITUMOR ACTIVITY, PHARMACOPHORE MODELING AND QSAR STUDIES OF NOVEL PYRAZOLES AND PYRAZOLO [1, 5-A] PYRIMIDINES AGAINST BREAST ADENOCARCINOMA MCF-7 CELL LINE
Abstract
Objective: The present work aimed to synthesize New series of pyrazoles 3 and pyrazolo[1,5-a]pyrimidines 5, 7, 9 in order to evaluate their antiproliferative activity against human breast adenocarcinoma MCF-7cell line and study the cell cycle progression of the most active compounds. In addition, Pharmacophore modeling and QSAR Studies of these new compounds were done.
Methods: The diazonium salt of 4-aminoacetophenone 1 was coupled with malononitrile in ethanol using sodium acetate affords 2-[(4-acetylphenyl)diazenyl] malononitrile Cycloaddition of hydrazine hydrate, in molar ratios 1:1 or 1:2, on compound 2, furnished 3,5-diaminopyrazolederivatives 3a and 3b respectively. Moreover, new pyrazolo[1,5-a]pyrimidine derivatives 5a-f were obtained upon cyclocondensation of 3a, b with different chalcones 4a-c in EtOH/piperidine,while compounds 7a-f were prepared via cycloaddition of 3a, b with various arylidene malononitriles 6a-c in the same reaction condition. Finally, treatment of 3a, b with ethyl 2-cyano-3-ethoxyacrylate 8a or 2-(ethoxymethylene)malononitrile 8b in EtOH/TEA yielded the novel pyrazolo[1,5-a]pyrimidine derivatives 9a, b respectively. These target compounds were screened for their cytotoxic activity against MCF-7 (human breast Cell Line) followed by study cell cycle of 7a. Finally, Pharmacophore modeling and QSAR Studies was carried out.
Results: The pyrazolopyrimidine 7a was the most active compound (IC50 = 3.25 µM), whereas, some of the tested compounds exploited moderate growth inhibitory activity. Its effect was further studied on cell cycle progression; results showed that compound 7a induced cell cycle arrest at S-phase verifying this compound as a promising selective anticancer agent.
Conclusion: Compound 7a was found to be the most active member against MCF-7 breast cancer (IC50= 3.25 μM), Further biological assessment of 7a using flow-cytometric analysis, revealed that it induced cell cycle arrest at S phase.
Keywords: Pyrazole, Pyrazolo[1,5-a]pyrimidine, MCF-7 breast cancer cell line, Cell cycle profile, 3D pharmacophore,1 QSAR study
Downloads
References
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007;57:43-66.
David ET. Chemistry and pharmacology of anticancer drugs. 1st ed. Taylor and Francis group editor. New York: CRC PRESS; 2007.
Keshtgar M, Davidson T, Pigott K, Falzon M, Jones A. Current status and advances in the management of early breast cancer. Int J Surg 2010;8:199-202.
Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician 2010;81:1339–46.
Nahren MM, Nanda G. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation-A case study with CDK2/Cyclin A. Eur J Med Chem 2008;43:2807-18.
Bronson J, Dhar M, Ewing W, Lonberg N. Chapter thirty-one – to market, to market-2011. Annu Res Med Chem 2012;47:548.
Ruth PF, Pilar G, José E. A review of recent progress (2002-2012) on the biological activities of pyrazoles. Arkivoc 2014;2:233-93.
Bronson J, Dhar M, Ewing W, Lonberg N. Annu Res Med Chem. 1st ed. Elsevier Inc; 2012.
Berger DM, Torres N, Dutia M, Powell D, Ciszewski G, Gopalsamy A, et al. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors. Bioorg Med Chem Lett 2009;19:6519–23.
Williamson DS, Parratt MJ, Bower JF, Moore JD, Richardson CM, Dokurno P, et al. Structure-guided design of pyrazolo[1,5-a] pyrimidines as inhibitors of the human cyclin-dependent kinase. J Bioorg Med Chem Lett 2005;15:863-7.
Li R, Ellen RL, Alex JB, Victoria D, Susan LG, Jonas Grina, et al. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties. Bioorg Med Chem Lett 2012;22:1165–8.
Al-Sehemi AG, Irfan A, Fouda AM. Synthesis, characterization and density functional theory investigations of the electronic, photophysical and charge transfer properties of donor–bridge–acceptor triaminopyrazolo[1,5-a]pyrimidine dyes. Spectrochim Acta Part A 2013;111:223–9.
Khurana JM, Kiran D, Susruta M. An efficient 1,3-allylic carbonyl transposition of chalcones. Monatsh Chem 2009;140:69-72.
Xiangâ€Shan W, Zhaoâ€Sen Z, Yuâ€Ling Li, Daâ€Qing S, Shuâ€Jiang Tu, Xianâ€Yong W, et al. Simple procedure for the synthesis of aryl methylene malononitrile without a catalyst. Synth Commun 2005;35:1915-20.
Claudia R, Renate D, Hans J, Heinz G. Possible rearrangements during the synthesis of di-and trisubstituted pyrazoles. Montash Chem 1998;129:1313-8.
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
Dominic AS, Robert HS, Kenneth DP, Anne M, Siobhan T, Thomas HN, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-33.
Adel SG, Jacek S, Nasser SM, Hanaa F. Synthesis and QSAR study of novel cytotoxic spiro[3H-indole-3,20(10H)-pyrrolo[3,4-c]pyrrole]-2,3`,5`(1H,2`aH,4`H)-triones. Eur J Med Chem 2012;47:312-22.
Saleh NM, Ammar YA, Micky JA, Abbas HA, EL-Gaby MS. Novel synthesis and antimicrobial investigation of pyrazolo[1,5-a]pyrimidine and pyrazolotriazine containing piperidinyl sulfone moiety. Indian J Chem 2004;43B:2195-202.
Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, et al. 4-Arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem 2006;49:6500-9.
El-Shafei A, Fadda AA, Khalil AM, Ameen TAE, Badria FA. Synthesis, antitumor evaluation, molecular modeling and quantitative structure-activity relationship (QSAR) of some novel arylazopyrazolo diazine and triazine analogs. Bioorg Med Chem 2009;17:5096–105.
Karcı F, Demircal A. Synthesis of disazopyrazolo[1,5-a]pyrimidines. Dyes Pigm 2007;74:288-97.
Fadda AA. Synthesis of some new arylazothiophene and arylazopyrazole derivatives as antitumor agents. Pharmacol Pharm 2012;3:148-57.
Tsai PC, Wang IJ. A facile synthesis of some new pyrazolo[1,5-a]pyrimidine heterocyclic disazo dyes and an evaluation of their solvatochromic behavior. Dyes Pigm 2007;74:578-84.
Dawane BS, Konda SG, Zangade SB. Design, synthesis, and characterization of some novel pyrazolo[1,5-a] pyrimidines as potent antimicrobial agents. J Heterocycl Chem 2010; 47:1250-4.
Elfahham HA, Elgemeie GH, Ibraheim YR, Elnagdi MH. Studies on 3,5-diaminopyrazoles: new routes for the synthesis of new pyrazoloazines and pyrazoloazoles. Liebigs Ann Chem 1988;8:819-22.
Hassan AS, Hafez TS, Osman SA, Ali MM. Synthesis and in vitro cytotoxic activity of novel pyrazolo[1,5-a]pyrimidines and related Schiff bases. Turk J Chem 2015;39:1102-13.